Concepts (218)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endosonography | 19 | 2018 | 56 | 3.660 |
Why?
|
| Adenocarcinoma | 10 | 2010 | 301 | 1.270 |
Why?
|
| Pancreatic Neoplasms | 7 | 2006 | 131 | 1.100 |
Why?
|
| Biliary Tract | 2 | 2012 | 7 | 0.800 |
Why?
|
| Biliary Tract Diseases | 2 | 2012 | 8 | 0.800 |
Why?
|
| Cholestasis | 2 | 2012 | 18 | 0.770 |
Why?
|
| Pancreatic Cyst | 3 | 2018 | 4 | 0.710 |
Why?
|
| Biopsy, Fine-Needle | 6 | 2009 | 50 | 0.660 |
Why?
|
| Incidental Findings | 1 | 2017 | 26 | 0.610 |
Why?
|
| Digestive System Diseases | 1 | 2016 | 5 | 0.580 |
Why?
|
| Lymphatic Diseases | 2 | 2012 | 9 | 0.510 |
Why?
|
| Lymph Nodes | 2 | 2012 | 92 | 0.480 |
Why?
|
| Kidney Transplantation | 1 | 2017 | 348 | 0.450 |
Why?
|
| Endoscopy, Gastrointestinal | 4 | 2018 | 26 | 0.440 |
Why?
|
| Pancreatitis, Acute Necrotizing | 2 | 2018 | 7 | 0.420 |
Why?
|
| Humans | 39 | 2018 | 29093 | 0.400 |
Why?
|
| Colonoscopy | 2 | 2018 | 41 | 0.370 |
Why?
|
| Retrospective Studies | 11 | 2018 | 3111 | 0.370 |
Why?
|
| Pancreatic Pseudocyst | 1 | 2010 | 4 | 0.370 |
Why?
|
| Gastrostomy | 1 | 2010 | 17 | 0.370 |
Why?
|
| Sensitivity and Specificity | 6 | 2012 | 532 | 0.350 |
Why?
|
| Pseudomyxoma Peritonei | 1 | 2008 | 12 | 0.340 |
Why?
|
| Liver Diseases | 1 | 2009 | 61 | 0.340 |
Why?
|
| Female | 25 | 2018 | 18164 | 0.310 |
Why?
|
| Appendiceal Neoplasms | 1 | 2008 | 81 | 0.310 |
Why?
|
| Pancreatitis, Chronic | 3 | 2016 | 8 | 0.310 |
Why?
|
| Male | 23 | 2018 | 17807 | 0.310 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 4 | 2016 | 31 | 0.300 |
Why?
|
| Esophageal Neoplasms | 4 | 2010 | 33 | 0.300 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2010 | 401 | 0.300 |
Why?
|
| Adult | 16 | 2018 | 8420 | 0.300 |
Why?
|
| Middle Aged | 20 | 2018 | 10829 | 0.300 |
Why?
|
| Liver | 2 | 2009 | 464 | 0.290 |
Why?
|
| Aged | 16 | 2018 | 9487 | 0.280 |
Why?
|
| Follow-Up Studies | 5 | 2017 | 2108 | 0.280 |
Why?
|
| Telomerase | 1 | 2006 | 21 | 0.280 |
Why?
|
| DNA, Neoplasm | 1 | 2006 | 58 | 0.280 |
Why?
|
| Peritoneal Neoplasms | 1 | 2008 | 241 | 0.270 |
Why?
|
| DNA | 1 | 2006 | 204 | 0.260 |
Why?
|
| Cholecystectomy, Laparoscopic | 2 | 2016 | 12 | 0.240 |
Why?
|
| Fluorodeoxyglucose F18 | 3 | 2010 | 56 | 0.230 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2003 | 97 | 0.230 |
Why?
|
| Hepatitis C | 1 | 2003 | 38 | 0.220 |
Why?
|
| Diagnosis, Differential | 3 | 2012 | 493 | 0.220 |
Why?
|
| Veterans | 1 | 2003 | 50 | 0.220 |
Why?
|
| Aged, 80 and over | 9 | 2016 | 3717 | 0.210 |
Why?
|
| Necrosis | 1 | 2018 | 53 | 0.170 |
Why?
|
| Antineoplastic Agents | 1 | 2003 | 546 | 0.170 |
Why?
|
| Pancreatectomy | 1 | 2018 | 29 | 0.160 |
Why?
|
| Journal Impact Factor | 1 | 2018 | 9 | 0.160 |
Why?
|
| Pancreatitis | 3 | 2011 | 18 | 0.160 |
Why?
|
| Deoxycytidine | 3 | 2010 | 63 | 0.160 |
Why?
|
| Predictive Value of Tests | 4 | 2016 | 787 | 0.160 |
Why?
|
| Curriculum | 2 | 2012 | 196 | 0.160 |
Why?
|
| Pancreas | 4 | 2010 | 79 | 0.160 |
Why?
|
| Radiopharmaceuticals | 3 | 2010 | 87 | 0.160 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 150 | 0.150 |
Why?
|
| Periodicals as Topic | 1 | 2018 | 95 | 0.150 |
Why?
|
| Choledocholithiasis | 1 | 2016 | 3 | 0.140 |
Why?
|
| Preoperative Care | 1 | 2017 | 110 | 0.140 |
Why?
|
| Self Concept | 1 | 2016 | 41 | 0.140 |
Why?
|
| Intraoperative Care | 1 | 2016 | 48 | 0.140 |
Why?
|
| Needles | 1 | 2016 | 28 | 0.140 |
Why?
|
| Activities of Daily Living | 1 | 2016 | 238 | 0.130 |
Why?
|
| Colonic Polyps | 2 | 2018 | 16 | 0.130 |
Why?
|
| Esophagectomy | 2 | 2010 | 15 | 0.110 |
Why?
|
| Prognosis | 1 | 2017 | 1362 | 0.110 |
Why?
|
| Abdomen | 1 | 2012 | 42 | 0.110 |
Why?
|
| Child, Preschool | 1 | 2016 | 1167 | 0.110 |
Why?
|
| Child | 2 | 2016 | 2219 | 0.110 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2010 | 68 | 0.110 |
Why?
|
| Ultrasonography, Interventional | 1 | 2012 | 51 | 0.110 |
Why?
|
| Positron-Emission Tomography | 2 | 2010 | 172 | 0.100 |
Why?
|
| Cholelithiasis | 1 | 2011 | 10 | 0.100 |
Why?
|
| Combined Modality Therapy | 6 | 2011 | 525 | 0.100 |
Why?
|
| Adolescent | 2 | 2016 | 3254 | 0.100 |
Why?
|
| Prospective Studies | 4 | 2016 | 2019 | 0.100 |
Why?
|
| Quality of Life | 1 | 2016 | 816 | 0.100 |
Why?
|
| Comorbidity | 2 | 2011 | 540 | 0.100 |
Why?
|
| Young Adult | 1 | 2017 | 2402 | 0.090 |
Why?
|
| Catheterization | 1 | 2010 | 58 | 0.090 |
Why?
|
| Immunohistochemistry | 2 | 2009 | 519 | 0.090 |
Why?
|
| Multivariate Analysis | 3 | 2010 | 637 | 0.090 |
Why?
|
| Survival Rate | 3 | 2006 | 795 | 0.090 |
Why?
|
| Gallbladder Neoplasms | 1 | 2009 | 33 | 0.090 |
Why?
|
| Bile Duct Neoplasms | 1 | 2009 | 36 | 0.090 |
Why?
|
| Drug Administration Schedule | 2 | 2006 | 246 | 0.080 |
Why?
|
| Radiography | 1 | 2009 | 353 | 0.080 |
Why?
|
| Evidence-Based Medicine | 1 | 2009 | 207 | 0.080 |
Why?
|
| Forecasting | 1 | 2008 | 133 | 0.080 |
Why?
|
| Clinical Competence | 2 | 2007 | 307 | 0.080 |
Why?
|
| Liver Neoplasms | 1 | 2009 | 162 | 0.080 |
Why?
|
| Genes, ras | 1 | 2006 | 26 | 0.070 |
Why?
|
| Kidney Neoplasms | 1 | 2009 | 192 | 0.070 |
Why?
|
| False Positive Reactions | 1 | 2006 | 25 | 0.070 |
Why?
|
| Celiac Plexus | 1 | 2006 | 3 | 0.070 |
Why?
|
| Disease Progression | 2 | 2006 | 572 | 0.070 |
Why?
|
| Autoimmune Diseases | 1 | 2006 | 50 | 0.070 |
Why?
|
| Bile Duct Diseases | 1 | 2006 | 9 | 0.070 |
Why?
|
| Nerve Block | 1 | 2006 | 48 | 0.070 |
Why?
|
| Neoadjuvant Therapy | 1 | 2006 | 56 | 0.070 |
Why?
|
| Risk Assessment | 2 | 2009 | 1305 | 0.070 |
Why?
|
| Cross-Sectional Studies | 2 | 2016 | 1356 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 1 | 2006 | 172 | 0.070 |
Why?
|
| Thrombocytopenia | 1 | 2005 | 32 | 0.070 |
Why?
|
| Vomiting | 1 | 2005 | 24 | 0.070 |
Why?
|
| Camptothecin | 1 | 2005 | 48 | 0.070 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 2005 | 2 | 0.070 |
Why?
|
| Education, Medical | 1 | 2006 | 67 | 0.070 |
Why?
|
| Colchicine | 1 | 2005 | 8 | 0.070 |
Why?
|
| Nausea | 1 | 2005 | 49 | 0.070 |
Why?
|
| Gastrointestinal Diseases | 1 | 2005 | 38 | 0.070 |
Why?
|
| Abdominal Pain | 1 | 2005 | 40 | 0.070 |
Why?
|
| Diarrhea | 1 | 2005 | 56 | 0.070 |
Why?
|
| Fatigue | 1 | 2005 | 68 | 0.070 |
Why?
|
| Rectal Neoplasms | 1 | 2005 | 14 | 0.060 |
Why?
|
| Disease-Free Survival | 1 | 2005 | 281 | 0.060 |
Why?
|
| Severity of Illness Index | 1 | 2008 | 863 | 0.060 |
Why?
|
| Mutation | 1 | 2006 | 466 | 0.060 |
Why?
|
| Cholangiography | 2 | 2016 | 6 | 0.060 |
Why?
|
| Pain | 1 | 2006 | 282 | 0.060 |
Why?
|
| Genes, erbB-1 | 1 | 2003 | 15 | 0.060 |
Why?
|
| Diphtheria Toxin | 1 | 2003 | 23 | 0.060 |
Why?
|
| Injections | 1 | 2003 | 61 | 0.060 |
Why?
|
| Radiotherapy Dosage | 3 | 2010 | 98 | 0.060 |
Why?
|
| Internship and Residency | 1 | 2007 | 283 | 0.060 |
Why?
|
| Treatment Outcome | 4 | 2018 | 3099 | 0.060 |
Why?
|
| Georgia | 1 | 2003 | 13 | 0.060 |
Why?
|
| Angioedema | 1 | 2003 | 3 | 0.060 |
Why?
|
| Enalapril | 1 | 2003 | 7 | 0.060 |
Why?
|
| Viscera | 1 | 2003 | 17 | 0.060 |
Why?
|
| Florida | 1 | 2003 | 33 | 0.060 |
Why?
|
| Prisoners | 1 | 2003 | 11 | 0.060 |
Why?
|
| Hospitals, Veterans | 1 | 2003 | 33 | 0.060 |
Why?
|
| Neoplasm Staging | 3 | 2010 | 436 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2010 | 163 | 0.060 |
Why?
|
| Stomach Diseases | 1 | 2002 | 7 | 0.060 |
Why?
|
| Cell Survival | 1 | 2003 | 272 | 0.060 |
Why?
|
| Choristoma | 1 | 2002 | 17 | 0.060 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2003 | 134 | 0.050 |
Why?
|
| Biopsy, Needle | 1 | 2002 | 89 | 0.050 |
Why?
|
| Gastrectomy | 1 | 2002 | 65 | 0.050 |
Why?
|
| Liver Transplantation | 1 | 2003 | 111 | 0.050 |
Why?
|
| Substance-Related Disorders | 1 | 2003 | 113 | 0.050 |
Why?
|
| Socioeconomic Factors | 1 | 2003 | 391 | 0.050 |
Why?
|
| Cell Line, Tumor | 1 | 2003 | 680 | 0.050 |
Why?
|
| Double-Blind Method | 2 | 2016 | 501 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2016 | 726 | 0.040 |
Why?
|
| Disinfection | 1 | 2018 | 5 | 0.040 |
Why?
|
| Barrett Esophagus | 1 | 2018 | 3 | 0.040 |
Why?
|
| Equipment Contamination | 1 | 2018 | 11 | 0.040 |
Why?
|
| Microscopy, Confocal | 1 | 2018 | 62 | 0.040 |
Why?
|
| False Negative Reactions | 2 | 2011 | 21 | 0.040 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2018 | 23 | 0.040 |
Why?
|
| Adenoma | 1 | 2018 | 35 | 0.040 |
Why?
|
| Cohort Studies | 3 | 2009 | 1687 | 0.040 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2018 | 56 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2011 | 871 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2018 | 186 | 0.040 |
Why?
|
| Length of Stay | 1 | 2018 | 292 | 0.040 |
Why?
|
| Disease Management | 1 | 2018 | 114 | 0.040 |
Why?
|
| Stents | 1 | 2018 | 171 | 0.040 |
Why?
|
| Factor Analysis, Statistical | 1 | 2016 | 70 | 0.040 |
Why?
|
| United States | 2 | 2018 | 3630 | 0.040 |
Why?
|
| Videotape Recording | 1 | 2016 | 12 | 0.040 |
Why?
|
| Phantoms, Imaging | 1 | 2016 | 56 | 0.030 |
Why?
|
| Colorectal Neoplasms | 1 | 2018 | 208 | 0.030 |
Why?
|
| Psychometrics | 1 | 2016 | 129 | 0.030 |
Why?
|
| Risk Factors | 1 | 2003 | 3531 | 0.030 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2006 | 142 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2005 | 440 | 0.030 |
Why?
|
| Chronic Disease | 2 | 2005 | 369 | 0.030 |
Why?
|
| Education, Medical, Continuing | 1 | 2012 | 45 | 0.030 |
Why?
|
| Animals | 1 | 2003 | 7297 | 0.030 |
Why?
|
| Technetium Tc 99m Lidofenin | 1 | 2011 | 3 | 0.030 |
Why?
|
| Ursodeoxycholic Acid | 1 | 2011 | 4 | 0.030 |
Why?
|
| Cholagogues and Choleretics | 1 | 2011 | 4 | 0.030 |
Why?
|
| Cholangiopancreatography, Magnetic Resonance | 1 | 2011 | 7 | 0.030 |
Why?
|
| Ceftriaxone | 1 | 2011 | 11 | 0.020 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2011 | 29 | 0.020 |
Why?
|
| Radiography, Interventional | 1 | 2011 | 35 | 0.020 |
Why?
|
| Platinum Compounds | 1 | 2010 | 3 | 0.020 |
Why?
|
| Age of Onset | 1 | 2011 | 95 | 0.020 |
Why?
|
| Obesity | 1 | 2018 | 1063 | 0.020 |
Why?
|
| Remission Induction | 1 | 2010 | 78 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2010 | 50 | 0.020 |
Why?
|
| Medical Records | 1 | 2010 | 68 | 0.020 |
Why?
|
| Fluorouracil | 1 | 2010 | 73 | 0.020 |
Why?
|
| Neurosurgical Procedures | 1 | 2011 | 98 | 0.020 |
Why?
|
| Contrast Media | 1 | 2010 | 123 | 0.020 |
Why?
|
| Observer Variation | 1 | 2010 | 96 | 0.020 |
Why?
|
| Video Recording | 1 | 2010 | 52 | 0.020 |
Why?
|
| Adenoma, Oxyphilic | 1 | 2009 | 4 | 0.020 |
Why?
|
| Hospitals, Teaching | 1 | 2009 | 28 | 0.020 |
Why?
|
| Probability | 1 | 2009 | 150 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2009 | 140 | 0.020 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2009 | 109 | 0.020 |
Why?
|
| Conscious Sedation | 1 | 2007 | 24 | 0.020 |
Why?
|
| Monitoring, Intraoperative | 1 | 2007 | 39 | 0.020 |
Why?
|
| Anesthesia | 1 | 2007 | 65 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2006 | 73 | 0.020 |
Why?
|
| Survival | 1 | 2006 | 13 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2011 | 670 | 0.020 |
Why?
|
| Tomography, Emission-Computed | 1 | 2005 | 25 | 0.020 |
Why?
|
| Recurrence | 1 | 2006 | 235 | 0.020 |
Why?
|
| Morbidity | 1 | 2005 | 91 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2005 | 159 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2006 | 641 | 0.020 |
Why?
|
| Mediastinum | 1 | 2004 | 12 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2005 | 293 | 0.020 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2004 | 46 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2006 | 337 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2006 | 345 | 0.010 |
Why?
|
| Ethnic Groups | 1 | 2006 | 440 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2006 | 374 | 0.010 |
Why?
|
| Laparoscopy | 1 | 2002 | 169 | 0.010 |
Why?
|
| Algorithms | 1 | 2002 | 462 | 0.010 |
Why?
|
| Hypertension | 1 | 2003 | 906 | 0.010 |
Why?
|